ABL Diagnostics tests DeepChek on Element Biosciences AVITI

ABL Diagnostics says an ongoing verification study is testing whether its DeepChek sequencing workflow works on Element Biosciences’ AVITI platform. The effort is aimed at giving labs more flexibility across sequencing systems while keeping analysis workflows standardized.

Why it matters: - ABL Diagnostics is pushing a platform-agnostic sequencing strategy that could let laboratories use different next-generation sequencing systems without changing core analysis workflows. - The work focuses on infectious disease testing, where workflow consistency, coverage quality and variant detection can affect research and clinical lab output. - If DeepChek performs well on AVITI, ABL Diagnostics could broaden its addressable market across labs that already use, or want to compare, multiple sequencing platforms.

What happened: - ABL Diagnostics on June 9 announced progress in an analytical verification program for its proprietary DeepChek workflow on Element Biosciences’ AVITI sequencing platform. - The study compares DeepChek performance on AVITI with established systems including Illumina MiSeq and iSeq 100. - The company said the verification effort is ongoing and is part of its platform-agnostic strategy. - Element Biosciences’ AVITI uses Avidity Sequencing chemistry and a dual independent flow-cell architecture. - In a prior statement, Element Biosciences CEO and co-founder Molly He said AVITI is designed to work in any research environment as a “plug-and-play” system. More information

The details: - The internal study evaluates 48 clinical samples, split into two independent pools of 24. - The sample set covers HIV, HBV, RSV, SARS-CoV-2 and influenza. - The workflow is being assessed across whole genome sequencing, genotyping, subtyping and resistance-associated mutation analysis. - ABL Diagnostics is measuring genome coverage depth and uniformity. - The study also evaluates variant detection, allele frequency estimation and consensus sequence generation. - Dr. Sofiane Mohamed, ABL Diagnostics’ head of research and development, said the study shows the adaptability of the DeepChek workflow and the value of standardized analysis across hardware platforms. - ABL Diagnostics said the results are not a complete regulatory validation or a demonstration of clinical performance. - The company also said no clinical benefit claims are being made beyond the product’s cleared or approved intended use.

Between the lines: - The announcement is less about a finished product claim and more about de-risking compatibility across sequencing ecosystems. - Platform flexibility matters because labs often need to balance cost, throughput and installed equipment when choosing sequencing instruments. - The comparison against Illumina systems suggests ABL Diagnostics is trying to show that DeepChek can produce consistent outputs on a newer competitor platform, not just on one vendor’s hardware.

What's next: - The verification study will continue through final analysis. - ABL Diagnostics may use the results to support broader adoption of DeepChek across multiple sequencing platforms. - Any stronger claims will depend on the study’s completion and the company’s final analysis.

The bottom line: - ABL Diagnostics is testing whether DeepChek can move beyond a single-instrument workflow and function consistently on AVITI, which could expand its reach in infectious disease sequencing.